» Articles » PMID: 17343315

Occult Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2007 Mar 9
PMID 17343315
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Macrophage activation syndrome (MAS) is a well described, but purportedly uncommon manifestation of systemic juvenile idiopathic arthritis (SJIA). There is evidence to suggest that macrophage activation is integral to the pathogenesis of SJIA. Accordingly, many patients with SJIA may have evidence of mild MAS that is not appreciated clinically. We investigated the prevalence of occult MAS in children with SJIA by reviewing bone marrow aspirates (BMA).

Methods: Patients diagnosed with SJIA who underwent bone marrow aspiration were identified retrospectively. Patients admitted with a diagnosis of fever of unknown origin and discharged with a diagnosis other than SJIA or malignancy, and who had a BMA, were identified as controls. The BMA were reviewed by a single hematopathologist for evidence of MAS, ranging from activated macrophages to frank hemophagocytic cells.

Results: Eight of 15 (53%) patients with SJIA had BMA suggestive of MAS. Two of 15 patients (13%) were diagnosed clinically with MAS. Three patients (20%) were noted to have frank hemophagocytosis, only one of whom was diagnosed with MAS clinically. There were no statistically significant differences in the laboratory values for the patients with and without evidence of MAS on BMA. There was no evidence of increased macrophage activity or hemophagocytosis in any of the control BMA.

Conclusion: Occult MAS appears to be common in patients with SJIA who undergo BMA. This suggests that macrophage activation may be integral to the pathogenesis of SJIA, with implications for treatment.

Citing Articles

Update in Hyperferritinemic Syndromes: Recognition and Management - A Scoping Review.

Vassilopoulos A, McCormick W, Lakhani A Brown J Hosp Med. 2025; 1(3):37667.

PMID: 40046595 PMC: 11878877. DOI: 10.56305/001c.37667.


Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study.

Chandrakasan S, Allen C, Bhatla D, Carter J, Chien M, Cooper R Arthritis Rheumatol. 2024; 77(2):226-238.

PMID: 39245963 PMC: 11782109. DOI: 10.1002/art.42985.


Clinical and genetic analysis of macrophage activation syndrome complicating juvenile idiopathic inflammatory myopathies.

Li G, Yan X, Luo C, An Y, Zhang Z, Tang X Pediatr Res. 2024; .

PMID: 39181985 DOI: 10.1038/s41390-024-03515-7.


IL-1 Family Blockade in Cytokine Storm Syndromes.

Cron R Adv Exp Med Biol. 2024; 1448:553-563.

PMID: 39117838 DOI: 10.1007/978-3-031-59815-9_36.


Murine Models of Secondary Cytokine Storm Syndromes.

Brisse E, Verweyen E, De Visscher A, Kessel C, Wouters C, Matthys P Adv Exp Med Biol. 2024; 1448:497-522.

PMID: 39117836 DOI: 10.1007/978-3-031-59815-9_34.